Biology Reference
In-Depth Information
Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB,
Becker JW, Van der Ploeg LH, Tota MR (2004) Crystal structure of human phosphodiesterase
3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43:6091-6100
Schaper W (2005) Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs
Ther 19:357-363
Schultz JE, Dunkern T, Gawlitta-Gorka E, Sorg G (2011) The GAF-tandem domain of phospho-
diesterase 5 as a potential drug target. Francis SH, Conti M, HouslayMD (eds) Phosphodies-
terases as drug targets. Springer, Heidelberg
Scotland G, Houslay MD (1995) Chimeric constructs show that the unique N-terminal domain of
the cyclic AMP phosphodiesterase RD1 (rPDE-IV
A1
;RNPDE4A1A) can confer membrane
association upon the normally cytosolic protein chloramphenicol acetyl transferase (CAT).
Biochem J 308:673-681
Sekhar KR, Grondin P, Francis SH, Corbin JD (1996) Design and synthesis of xanthines and cyclic
GMP analogues as potent inhibitors of PDE5. In: Schudt C, Dent G, Rabe KF (eds) Phospho-
diesterase inhibitors. Academic, New York, pp 135-146
Serebruany V, Sabaeva E, Booze C, Atar OD, Eisert C, Hanley D (2009) Distribution of
dipyridamole in blood components among post-stroke patients treated with extended release
formulation. Thromb Haemost 102:538-543
Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by
the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol
Chem 271:16526-16534
Shakur Y, Pryde J, Houslay MD (1993) Engineered deletion of the unique N-terminal domain of
the cyclic AMP specific phosphodiesterase RD1 prevents plasma membrane association and
the attainment of enhanced thermostability without altering its sensitivity to inhibition by
rolipram. Biochem J 292:677-686
Smith KJ, Scotland G, Beattie J, Trayer IP, Houslay MD (1996) Determination of the structure of
the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1)
by
1
H-NMR and identification of the membrane association domain using chimeric constructs.
J Biol Chem 271:16703-16711
Smith KJ, Baillie GS, Hyde EI, Li X, Houslay TM, McCahill A, Dunlop AJ, Bolger GB,
Klussmann E, Adams DR, Houslay MD (2007)
1
H NMR structural and functional character-
isation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that
disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1.
Cell Signal 19:2612-2624
Souness JE, Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic
AMP phosphodiesterases. Cell Signal 9:227-236
Stasch JP, Hobbs AJ (2009) NO-independent, haem-dependent soluble guanylate cyclase stimu-
lators. Handb Exp Pharmacol 191:277-308
Steinberg SF, Brunton LL (2001) Compartmentation of G protein-coupled signaling pathways in
cardiac myocytes. Annu Rev Pharmacol Toxicol 41:751-773
Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H (2000) Potent effects
of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide
phosphodiesterase isozyme activity. Biochem Pharmacol 59:347-356
Sullivan M, Egerton M, Shakur Y, Marquardsen A, Houslay MD (1994) Molecular cloning and
expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA, cyclic AMP
specific phosphodiesterase (hPDE-IVA-h6.1). Cell Signal 6:793-812
Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E,
Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM (2003) Structure of the catalytic domain of
human phosphodiesterase 5 with bound drug molecules. Nature 425:98-102
Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T,
Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA (2005a) cGMP catabolism by
phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mecha-
nism. Circ Res 96:100-109
